<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T05:37:22Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4608906" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4608906</identifier>
        <datestamp>2016-10-18</datestamp>
        <setSpec>fasebj</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">FASEB J</journal-id>
              <journal-id journal-id-type="iso-abbrev">FASEB J</journal-id>
              <journal-id journal-id-type="hwp">fasebj</journal-id>
              <journal-id journal-id-type="pmc">fasebj</journal-id>
              <journal-id journal-id-type="publisher-id">FASEB</journal-id>
              <journal-title-group>
                <journal-title>The FASEB Journal</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0892-6638</issn>
              <issn pub-type="epub">1530-6860</issn>
              <publisher>
                <publisher-name>Federation of American Societies for Experimental
Biology</publisher-name>
                <publisher-loc>Bethesda, MD, USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4608906</article-id>
              <article-id pub-id-type="pmcid">PMC4608906</article-id>
              <article-id pub-id-type="pmc-uid">4608906</article-id>
              <article-id pub-id-type="pmid">26183771</article-id>
              <article-id pub-id-type="publisher-id">FJ_275065</article-id>
              <article-id pub-id-type="doi">10.1096/fj.15-275065</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Communication</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Inherited human group IVA cytosolic phospholipase A<sub>2</sub>
deficiency abolishes platelet, endothelial, and leucocyte eicosanoid
generation</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kirkby</surname>
                    <given-names>Nicholas S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">*</xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>†</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Reed</surname>
                    <given-names>Daniel M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Edin</surname>
                    <given-names>Matthew L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rauzi</surname>
                    <given-names>Francesca</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">
                    <sup>†</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mataragka</surname>
                    <given-names>Stefania</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vojnovic</surname>
                    <given-names>Ivana</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">
                    <sup>†</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bishop-Bailey</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">
                    <sup>§</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Milne</surname>
                    <given-names>Ginger L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff5">
                    <sup>¶</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Longhurst</surname>
                    <given-names>Hilary</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff6">
                    <sup>‖</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zeldin</surname>
                    <given-names>Darryl C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mitchell</surname>
                    <given-names>Jane A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">*</xref>
                  <xref ref-type="author-notes" rid="afn1">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Warner</surname>
                    <given-names>Timothy D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">
                    <sup>†</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="afn1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor1">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><label>*</label>National Heart and Lung Institute, Imperial
College London, London, United Kingdom;</aff>
                <aff id="aff2"><label>†</label>William Harvey Research Institute, Queen Mary
University of London, London, United Kingdom;</aff>
                <aff id="aff3"><label>‡</label>National Institutes of Health, National Institute
of Environmental Health Sciences, Research Triangle Park, North Carolina, USA;</aff>
                <aff id="aff4"><label>§</label>Department of Comparative Biomedical Sciences,
Royal Veterinary College, London, United Kingdom;</aff>
                <aff id="aff5"><label>¶</label>Department of Pharmacology and Department of
Medicine, Vanderbilt University, Nashville, Tennessee, USA; and</aff>
                <aff id="aff6"><label>‖</label>Immunology Department, Barts Health and the London
National Health Service Trust, London, United Kingdom</aff>
              </contrib-group>
              <author-notes>
                <fn id="afn1" fn-type="equal">
                  <label>1</label>
                  <p>These authors contributed equally to this work.</p>
                </fn>
                <corresp id="cor1"><label>2</label>Correspondence: <addr-line>The William Harvey
Research Institute, Barts, and the London School of Medicine and Dentistry,
Charterhouse Square, London EC1M 6BQ, United Kingdom.</addr-line> E-mail:
<email>t.d.warner@qmul.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>17</day>
                <month>10</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>11</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>17</day>
                <month>10</month>
                <year>2016</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
              <volume>29</volume>
              <issue>11</issue>
              <fpage>4568</fpage>
              <lpage>4578</lpage>
              <history>
                <date date-type="received">
                  <day>21</day>
                  <month>5</month>
                  <year>2015</year>
                </date>
                <date date-type="accepted">
                  <day>06</day>
                  <month>7</month>
                  <year>2015</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s)</copyright-statement>
                <copyright-year>2015</copyright-year>
                <copyright-holder>FASEB</copyright-holder>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution 4.0 International (CC BY 4.0) (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>) which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="fasebj275065.pdf"/>
              <abstract>
                <p>Eicosanoids are important vascular regulators, but the phospholipase A<sub>2</sub>
(PLA<sub>2</sub>) isoforms supporting their production within the cardiovascular
system are not fully understood. To address this, we have studied platelets,
endothelial cells, and leukocytes from 2 siblings with a homozygous loss-of-function
mutation in group IVA cytosolic phospholipase A<sub>2</sub>
(cPLA<sub>2</sub>α). Chromatography/mass spectrometry was used to determine
levels of a broad range of eicosanoids produced by isolated vascular cells, and in
plasma and urine. Eicosanoid release data were paired with studies of cellular
function. Absence of cPLA<sub>2</sub>α almost abolished eicosanoid synthesis
in platelets (<italic>e.g.</italic>, thromboxane A<sub>2</sub>, control 20.5 ±
1.4 ng/ml <italic>vs.</italic> patient 0.1 ng/ml) and leukocytes
[<italic>e.g.</italic>, prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), control
21.9 ± 7.4 ng/ml <italic>vs.</italic> patient 1.9 ng/ml], and this was
associated with impaired platelet activation and enhanced inflammatory responses.
cPLA<sub>2</sub>α-deficient endothelial cells showed reduced, but not
absent, formation of prostaglandin I<sub>2</sub> (prostacyclin; control 956 ±
422 pg/ml <italic>vs.</italic> patient 196 pg/ml) and were primed for inflammation.
In the urine, prostaglandin metabolites were selectively influenced by
cPLA<sub>2</sub>α deficiency. For example, prostacyclin metabolites were
strongly reduced (18.4% of control) in patients lacking cPLA<sub>2</sub>α,
whereas PGE<sub>2</sub> metabolites (77.8% of control) were similar to healthy
volunteer levels. These studies constitute a definitive account, demonstrating the
fundamental role of cPLA<sub>2</sub>α to eicosanoid formation and cellular
responses within the human circulation.—Kirkby, N. S., Reed, D. M., Edin, M.
L., Rauzi, F., Mataragka, S., Vojnovic, I., Bishop-Bailey, D., Milne, G. L.,
Longhurst, H., Zeldin, D. C., Mitchell, J. A., Warner, T. D. Inherited human group
IVA cytosolic phospholipase A<sub>2</sub> deficiency abolishes platelet, endothelial,
and leucocyte eicosanoid generation.</p>
              </abstract>
              <kwd-group>
                <kwd>cardiovascular</kwd>
                <kwd>thromboxane A<sub>2</sub></kwd>
                <kwd>prostacyclin</kwd>
                <kwd>inflammation</kwd>
              </kwd-group>
              <counts>
                <page-count count="11"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name> DJS Export </meta-name>
                  <meta-value>v1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <p>In the cardiovascular system, eicosanoids have well-characterized roles in both normal
function and a range of disease states (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). For example, thromboxane A<sub>2</sub>
(TXA<sub>2</sub>), generated by platelets, drives thrombotic responses to particular
stimuli (<italic>e.g.</italic>, collagen) and contributes to atherogenesis, whereas
prostaglandin I<sub>2</sub> (prostacyclin), generated by endothelial cells, causes
vasodilatation, inhibits platelet activation, and suppresses vascular inflammation. In
leukocytes, eicosanoid formation [predominantly prostaglandin E<sub>2</sub>
(PGE<sub>2</sub>)] is induced by proinflammatory stimuli such as LPS that up-regulate
cyclooxygenase (COX)-2 and other biosynthetic pathways (<xref rid="B3" ref-type="bibr">3</xref>) and so modulate the inflammatory response. In each case, although specific
eicosanoid pathways such as TXA<sub>2</sub>, PGE<sub>2</sub>, and prostacyclin are well
characterized, platelets, endothelial cells, and leukocytes synthesize substantial amounts
of other arachidonic acid–derived mediators, the effect of which in combination
remains poorly understood.</p>
            <p>The arachidonic acid required for eicosanoid production is released from the sn-2 position
of membrane glycerophospholipids by the actions of phospholipase A<sub>2</sub>
(PLA<sub>2</sub>) enzymes. As reviewed (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>), &gt;30 PLA<sub>2</sub> enzymes have been
identified and currently classified into 6 broad families: secreted phospholipase
A<sub>2</sub> (sPLA<sub>2</sub>), Ca<sup>2+</sup>-dependent cytosolic phospholipase
A<sub>2</sub> (cPLA<sub>2</sub>), calcium-independent phospholipase A<sub>2</sub>
(iPLA<sub>2</sub>), platelet-activating factor acetylhydrolases, lysosomal
PLA<sub>2</sub>, and adipose-specific phospholipase. Of the known isoforms, group IVA
cPLA<sub>2</sub> (also referred to as cPLA<sub>2</sub>α), encoded by the PLA2G4A
gene, is the most studied and has been characterized as a cytosolic enzyme, which upon
Ca<sup>2+</sup>-dependent activation cleaves arachidonate-containing phospholipids to
generate free intracellular arachidonic acid. This arachidonic acid is then used as a
substrate by enzymes that synthesize the eicosanoid mediators, including COXs that produce
prostanoids such as TXA<sub>2</sub> and prostacyclin, lipoxygenases (LOXs) that generate
hydroxyeicosatetraenoic acids (<italic>e.g.</italic>, 12-HETE), and cytochrome P450 enzymes
that generate epoxyeicosatrienoic acids (EETs) and HETEs (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). cPLA<sub>2</sub>α is widely
expressed through the vasculature, in platelets, and in most types of blood leukocytes.
Nonetheless, vascular and blood cells are known to express other PLA<sub>2</sub> enzymes,
such as sPLA<sub>2</sub> enzymes including group II (platelets) and group V (endothelium)
isoforms as well as iPLA<sub>2</sub> isoforms, which could also liberate arachidonic acid.
For example, exogenous sPLA<sub>2</sub> has been demonstrated to activate platelets (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>) and
endothelial cells (<xref rid="B8" ref-type="bibr">8</xref>). A role for endogenous
sPLA<sub>2</sub> and iPLA<sub>2</sub> enzymes in eicosanoid generation by
agonist-stimulated platelets (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>),
endothelial cells (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>), and leukocytes (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>) has also been described by several groups, calling
into question the relative role of PLA<sub>2</sub> isoforms in eicosanoid generation and
vascular protection. Indeed, the recent failure of the sPLA<sub>2</sub> inhibitor
varespladib for the prevention of cardiovascular events in patients with acute coronary
syndromes underlines our inadequate knowledge of the role of PLA<sub>2</sub> enzymes in
vascular health and disease (<xref rid="B15" ref-type="bibr">15</xref>).</p>
            <p>The key role of cPLA<sub>2</sub>α in the generation of eicosanoid mediators is
supported by data from cPLA<sub>2</sub>α-knockout mice (<xref rid="B9" ref-type="bibr">9</xref>) and pharmacologic inhibitors (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). Furthermore, we have recently
reported 2 siblings with a homozygous mutation of the PLA2G4A gene that leads to a complete
absence of cPLA<sub>2</sub>α activity (<xref rid="B18" ref-type="bibr">18</xref>).
Our work (<xref rid="B18" ref-type="bibr">18</xref>) and similar work from 2 other groups
(<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>)
using tissue from patients with a heterozygous mutation of the PLA2G4A gene has shown that
cPLA<sub>2</sub>α regulates production of particular eicosanoids in platelets and
in the urine. However, the relative role of cPLA<sub>2</sub>α in endothelial cell
and leukocyte eicosanoid function, as well as more broadly in platelets, has not thus far
been addressed. By performing such studies, we have now definitively defined and compared
the contribution of cPLA<sub>2</sub>α with eicosanoid formation and inflammatory
responses in leukocytes, platelets, and in endothelial cells. Our data show, for the first
time, how loss of this fundamental enzyme system regulates phenotypes and inflammatory
responses of these cardiovascular cells and associated urinary markers relevant to vascular
disease.</p>
            <sec sec-type="materials|methods" id="s1">
              <title>MATERIALS AND METHODS</title>
              <sec id="s2">
                <title>Blood collection and ethics</title>
                <p>Blood was collected by venipuncture from healthy volunteers and from 2 patients
(brother, patient B; sister, patient S) bearing a homozygous mutation in the PLA2G4A
gene, which disrupts the active site of cPLA<sub>2</sub>α (<xref rid="B18" ref-type="bibr">18</xref>). All experiments were subject to written
informed consent, local ethical approval (healthy volunteer samples for
platelet/leukocyte studies; St. Thomas’s Hospital Research Ethics Committee,
reference 07/Q0702/24: endothelial cell studies; Royal Brompton and Harfield Hospital
Research Ethics Committee, reference 08/H0708/69: patient samples; South East
National Health Service Research Ethics Committee), and in accordance with
Declaration of Helsinki principles.</p>
              </sec>
              <sec id="s3">
                <title>Whole-blood stimulation</title>
                <p>Heparin-anticoagulated whole blood was incubated with vehicle (PBS), Horm collagen
(Nycomed, St. Peter, Austria), thrombin receptor-activating peptide (TRAP)-6 amide
(Bachem, Heidelberg, Germany), Ca<sup>2+</sup> ionophore, A23187 (Sigma-Aldrich,
Poole, United Kingdom), for 30 min, or with LPS (Sigma-Aldrich), triacylated
lipoprotein CSK4 (Pam3CSK4; InvivoGen, Toulouse, France), bisacylated lipoprotein
CGDPKHPKSF (FSL-1; InvivoGen), polyinosinic:polycytidylic acid [poly(I:C);
Sigma-Aldrich], or IL-1β (Invitrogen, Life Technologies, Paisley, United
Kingdom) for 18 h in the presence or absence of diclofenac (10 μM;
Sigma-Aldrich). Levels of (C-X-C motif) ligand-8 (CXCL8; R&amp;D Systems,
Abingdon, United Kingdom), PGE<sub>2</sub> (Cisbio, Saclay, France), or
TXB<sub>2</sub> (Cayman Chemical, Cambridge Bioscience, Cambridge, United Kingdom)
were measured by immunoassay or total eicosanoids by gas chromatography–tandem
mass spectrometry (see below) in the conditioned plasma.</p>
              </sec>
              <sec id="s4">
                <title>Eicosanoid analysis</title>
                <p>Basal and conditioned plasma was subject to eicosanomic analysis as previously
described (<xref rid="B21" ref-type="bibr">21</xref>). Urinary prostanoid levels were
determined by gas chromatography–tandem mass spectrometry as previously
described (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>).</p>
              </sec>
              <sec id="s5">
                <title>Light transmission aggregometry and ATP release</title>
                <p>Platelet-rich plasma was preincubated with the COX inhibitor aspirin (30 μM;
Sigma-Aldrich), the cPLA<sub>2</sub> inhibitor pyrrophenone (40 μM; Cayman
Chemical, Cambridge Bioscience), or vehicle for 30 min at 37°C. Aggregation
and ATP secretion responses to collagen (0.3–3 μg/ml), ADP (5
μM; Chrono-log; Labmedics, Abingdon, United Kingdom), U46619 (10 μM;
Enzo Life Sciences, Exeter, United Kingdom), or arachidonic acid (1 mM;
Sigma-Aldrich) were measured using a Chrono-log 560CA Lumi-Aggregometer (Chrono-log
Corp., Havertown, PA, USA).</p>
              </sec>
              <sec id="s6">
                <title>Platelet adhesion under flow</title>
                <p>Whole blood was preincubated with aspirin (100 μM), pyrrophenone (40
μM), or vehicle before labeling of cells with mepacrine (10 μM;
Sigma-Aldrich) for a further 30 min. This was then drawn through a slide chamber
(Ibidi, Munich, Germany) coated with collagen (100 μg/ml) by a syringe pump to
achieve a shear rate of 1000 s<sup>−1</sup>.</p>
              </sec>
              <sec id="s7">
                <title>Endothelial cells</title>
                <p>Blood outgrowth endothelial cells were grown out from progenitors in human blood as
previously described (<xref rid="B24" ref-type="bibr">24</xref><xref rid="B25" ref-type="bibr"/><xref rid="B26" ref-type="bibr"/>–<xref rid="B27" ref-type="bibr">27</xref>). Once colonies emerged (between d 4 and 20), cells were
expanded and maintained in Lonza EGM-2 medium (Lonza, Slough, United Kingdom) plus
10% fetal bovine serum, and experiments were performed between passages 2 and 8.</p>
              </sec>
              <sec id="s8">
                <title>Endothelial cell immunocytochemistry</title>
                <p>Endothelial cells were stained using anti-CD31 (platelet endothelial cell adhesion
molecule-1)–Alexa Fluor 488 (BioLegend, London, United Kingdom) or
anti-vascular endothelial-cadherin (Santa Cruz Biotechnology, Dallas, TX, USA) and
imaged using a Cellomics VTi HCS Arrayscanner (Thermo Fisher Scientific, Hemel
Hempstead, United Kingdom).</p>
              </sec>
              <sec id="s9">
                <title>Endothelial cell eicosanoid and cytokine production</title>
                <p>Cells were plated on 48- or 96-well plates. For eicosanoid measurements, endothelial
cells were primed with IL-1β (1 ng/ml) to up-regulate COX pathways, as
described previously (<xref rid="B28" ref-type="bibr">28</xref>), before being
treated for 30 min with A23187 or thrombin to activate PLA<sub>2</sub> or arachidonic
acid to supply eicosanoid substrate directly. For inflammation studies, endothelial
cells were treated with vehicle (Lonza EGM-2) or TLR ligands: heat-killed
<italic>Listeria monocytogenes</italic> (10<sup>7</sup> cells/ml), Pam3CSK4 (1
μg/ml), FSL-1 (1 μg/ml), poly(I:C) (10 μg/ml), LPS (1
μg/ml), <italic>Staphylococcus aureus</italic>–derived flagellin (FLA;
100 ng/ml), imiquimod (1 μg/ml), single-stranded RNA oligonucleotide-40 (1
μg/ml), and oligodeoxynucleotide-2006 (5 μM). After 24 h, media were
collected for measurement of CXCL8 release by ELISA (R&amp;D Systems).</p>
              </sec>
              <sec id="s10">
                <title>Statistics and data analysis</title>
                <p>Data are expressed as means ± <sc>se</sc>. Statistical analysis was performed
by 1- or 2-way ANOVA or by unpaired Student’s <italic>t</italic> test using
GraphPad Prism 6 software (GraphPad Software, La Jolla, CA, USA). Patient
eicosanomics data (<italic>n</italic> = 1–2) were interpreted qualitatively
without statistical testing.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s11">
              <title>RESULTS</title>
              <sec id="s12">
                <title>Role of cPLA<sub>2</sub>α in eicosanoid formation in platelets</title>
                <p>Incubation of blood with collagen (<xref ref-type="fig" rid="F1"><bold>Fig.
1<italic>A</italic></bold></xref>) or TRAP-6 (<xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic></xref>) to specifically activate platelets increased
levels of TXB<sub>2</sub> (the stable breakdown product of TXA<sub>2</sub>) and
12-HETE, in particular. There were also increases in PGE<sub>2</sub>, prostaglandin
D<sub>2</sub> (PGD<sub>2</sub>), 11-HETE, and 15-HETE. 12-HETE levels were
somewhat lower in TRAP-6–stimulated blood as compared with collagen-stimulated
blood. In blood treated with the Ca<sup>2+</sup> ionophore, A23187, to cause acute
receptor-independent activation of platelets and leukocytes, a broadly similar
pattern of eicosanoid formation was observed (<xref ref-type="fig" rid="F1">Fig.
1<italic>C</italic></xref>) with a marked production of 12-HETE, followed by
TXB<sub>2</sub>, 15-HETE, and 11-HETE. There were also greatly increased levels of
5-HETE, representing acute activation of leukocytes, and a more modest production of
5,6-EET. In each case, eicosanoid production to these stimuli was almost absent in
blood from cPLA<sub>2</sub>α-deficient patients (<xref ref-type="fig" rid="F1">Fig. 1</xref> and <ext-link ext-link-type="uri" xlink:href="http://FJ.fasebj.org/lookup/suppl/doi:10.1096/fj.15-275065/-/DC1">Supplemental Tables S1 and S2</ext-link>). Normal eicosanoid formation was
observed in the presence of exogenous arachidonic acid in both healthy volunteer and
cPLA<sub>2</sub>α-deficient patient blood. In isolated platelets
(platelet-rich plasma), TXB<sub>2</sub> formation induced by ADP, collagen, or the
TXA<sub>2</sub>-mimetic U46619, but not exogenous arachidonic acid, was abolished
by cPLA<sub>2</sub>α deficiency (<ext-link ext-link-type="uri" xlink:href="http://FJ.fasebj.org/lookup/suppl/doi:10.1096/fj.15-275065/-/DC1">Supplemental Fig. S1</ext-link>).</p>
                <fig id="F1" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Contribution of cPLA<sub>2</sub>α to eicosanoid synthesis in whole
blood. Eicosanoid levels in whole blood from healthy volunteers or from a
patient lacking cPLA<sub>2</sub>α stimulated with collagen (30
μg/ml) (<italic>A</italic>), TRAP-6 amide (30 μM)
(<italic>B</italic>), or A23187 Ca<sup>2+</sup> ionophore (50 μM)
(<italic>C</italic>). Levels are expressed as increase over levels in
vehicle-treated blood. <italic>n</italic> = 3–6 (healthy volunteers);
<italic>n</italic> = 1 (patient S).</p>
                  </caption>
                  <graphic xlink:href="fasebj275065f1"/>
                </fig>
              </sec>
              <sec id="s13">
                <title>Role of cPLA<sub>2</sub>α in platelet aggregation, secretion, and adhesion
responses</title>
                <p>Absence of cPLA<sub>2</sub>α or cPLA<sub>2</sub> inhibition by pyrrophenone
produced a marked reduction in collagen-induced aggregation similar to that produced
by aspirin (<xref ref-type="fig" rid="F2"><bold>Fig.
2<italic>A</italic></bold></xref>) but had little effect upon responses to ADP or
exogenous arachidonic acid (<xref ref-type="fig" rid="F2">Fig.
2<italic>B</italic></xref>). ATP release induced by collagen (<xref ref-type="fig" rid="F2">Fig. 2<italic>C</italic></xref>), but not that induced by ADP or
arachidonic acid (<xref ref-type="fig" rid="F2">Fig. 2<italic>D</italic></xref>), was
strongly blunted by loss of functional cPLA<sub>2</sub>α or aspirin treatment,
and under flow conditions, platelet adhesion to collagen was almost abolished by
cPLA<sub>2</sub>α inhibition/deficiency (<xref ref-type="fig" rid="F2">Fig.
2<italic>E</italic></xref>).</p>
                <fig id="F2" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Effect of cPLA<sub>2</sub>α deficiency on platelet aggregation,
secretion, and adhesion responses. Effect of cPLA<sub>2</sub>α
deficiency, cPLA<sub>2</sub>α inhibition, and aspirin on platelet
aggregation to collagen (0.1–3 μg/ml) (<italic>A</italic>), ADP
(5 μM) (<italic>B</italic>), and arachidonic acid (AA; 1 mM) is shown.
Pyrro, pyrrophenone. ATP secretion to collagen (0.1–3 μg/ml)
(<italic>C</italic>), ADP (5 μM) (<italic>D</italic>), and
arachidonic acid (1 mM). <italic>E</italic>) Platelet adhesion to collagen
under flow (1000 s<sup>−1</sup>). <italic>n</italic> = 2–4
(healthy volunteers); <italic>n</italic> = 2 (patient B and patient S).
*<italic>P</italic> &lt; 0.05 by 2-way ANOVA with
Dunnett’s posttest.</p>
                  </caption>
                  <graphic xlink:href="fasebj275065f2"/>
                </fig>
              </sec>
              <sec id="s14">
                <title>Role of cPLA<sub>2</sub>α in eicosanoid formation in endothelial
cells</title>
                <p>Endothelial cells from healthy volunteers or derived from
cPLA<sub>2</sub>α-deficient patients emerged in culture after 4–20 d,
grew with typical cobblestone morphology, expressed the endothelial cell markers CD31
and VE cadherin (<xref ref-type="fig" rid="F3"><bold>Fig.
3<italic>A</italic></bold></xref>), and aligned when cultured under directional
shear stress (<xref rid="B29" ref-type="bibr">29</xref>) (<xref ref-type="fig" rid="F3">Fig. 3<italic>B</italic></xref>). In the presence of A23187, endothelial
cells from healthy volunteers released predominately prostacyclin (measured as the
stable breakdown product 6-keto-PGF<sub>1</sub>α) followed by PGE<sub>2</sub>,
PGD<sub>2</sub>, 11-HETE, and 15-HETE. In each case, eicosanoid release was lower
but not abolished in endothelial cells derived from
cPLA<sub>2</sub>α-deficient patients (<xref ref-type="fig" rid="F3">Fig.
3<italic>C</italic></xref>) (<italic>e.g.</italic>, prostacyclin release from
cPLA<sub>2</sub>α-deficient endothelial cells was reduced by ∼80%).
Similarly, the cPLA<sub>2</sub> inhibitor, pyrrophenone, produced a
concentration-dependent inhibition of prostacyclin release from endothelial cells
grown from healthy donors (<ext-link ext-link-type="uri" xlink:href="http://FJ.fasebj.org/lookup/suppl/doi:10.1096/fj.15-275065/-/DC1">Supplemental Fig. S2</ext-link>), with a maximal effect of ∼80%.
Prostacyclin was also released from endothelial cells of healthy volunteers when
stimulated with the receptor-dependent activator, thrombin (<xref ref-type="fig" rid="F3">Fig. 3<italic>D</italic></xref>). As described for A23187-stimulated
release above, thrombin-stimulated prostacyclin release was reduced but not abolished
in cPLA<sub>2</sub>α-deficient patient endothelial cells. Endothelial cells of
both genotypes responded strongly to exogenous arachidonic acid (<xref ref-type="fig" rid="F3">Fig. 3<italic>D</italic></xref>).</p>
                <fig id="F3" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Phenotyping of and eicosanoid synthesis by endothelial cells grown out of blood
progenitors from healthy volunteers and from a
cPLA<sub>2</sub>α-deficient patient. <italic>A</italic>)
Endothelial-specific marker expression of CD31 (green) and VE cadherin (red)
and actin staining (green). <italic>B</italic>) Morphologic response to shear
stress after 3 d. <italic>C</italic>) Eicosanoid release in IL-1β (1
ng/ml)-primed endothelial cells stimulated with A23187 (50 μM).
<italic>D</italic>) Prostacyclin release from IL-1β–primed
endothelial cells stimulated for 30 min with A23187 (50 μM), thrombin (1
U/ml), or arachidonic acid (AA; 50 μM). Data are from at least 3 wells
per condition. <italic>n</italic> = 3–6 (healthy volunteers);
<italic>n</italic> = 1 (patient S).</p>
                  </caption>
                  <graphic xlink:href="fasebj275065f3"/>
                </fig>
              </sec>
              <sec id="s15">
                <title>Role of cPLA<sub>2</sub>α in eicosanoid formation by leukocytes</title>
                <p>When whole blood was stimulated (18 h) with the TLR4 agonist, LPS, to activate
leukocytes and inducible biosynthetic pathways, the major eicosanoids produced were
12- and 15-HETE and PGE<sub>2</sub>, and a smaller amount of 11-HETE (<xref ref-type="fig" rid="F4"><bold>Fig. 4<italic>A</italic></bold></xref> and <ext-link ext-link-type="uri" xlink:href="http://FJ.fasebj.org/lookup/suppl/doi:10.1096/fj.15-275065/-/DC1">Supplemental Table S3</ext-link>). In cPLA<sub>2</sub>α-deficient patient
blood, LPS-induced production of PGE<sub>2</sub> and 15-HETE was greatly reduced,
whereas the production of 12-HETE was little affected. Overall, productions were
restored by acute addition of arachidonic acid (<xref ref-type="fig" rid="F4">Fig.
4<italic>B</italic></xref> and <ext-link ext-link-type="uri" xlink:href="http://FJ.fasebj.org/lookup/suppl/doi:10.1096/fj.15-275065/-/DC1">Supplemental Table S3</ext-link>). Pam3CSK4 (TLR2/1) and FSL-1 (TLR2/6), which
activate pattern recognition receptors associated with gram-positive bacteria, as
with LPS, activated whole blood to release PGE<sub>2</sub>, an effect that was
abolished by cPLA<sub>2</sub>α deficiency (<xref ref-type="fig" rid="F4">Fig.
4<italic>C</italic></xref>). Neither Poly(I:C), which stimulates the viral
pathogen recognition receptor TLR3, nor IL-1β, which works independently of
pattern recognition receptors, stimulated PGE<sub>2</sub> release from whole
blood.</p>
                <fig id="F4" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 4.</label>
                  <caption>
                    <p>Contribution of cPLA<sub>2</sub>α to eicosanoid synthesis in leukocytes.
<italic>A</italic>) Eicosanoid levels in whole blood from healthy volunteers
or from a patient lacking cPLA<sub>2</sub>α treated with LPS (10
μg/ml) for 18 h. PGE<sub>2</sub> formation in whole blood treated with
LPS (10 μg/ml) for 18 h followed by addition of A23187 (50 μM) or
arachidonic acid (AA; 1 mM) for 30 min (<italic>B</italic>) or treated with
agonists to TLR2/1 (Pam3CSK4; 1 μg/ml), TLR2/6 (FSL-1; 1 μg/ml),
TLR3 [poly(I:C); 10 μg/ml], IL-1 receptor (IL-1β; 1 ng/ml), or
TLR4 (LPS; 5–20 μg/ml) (<italic>C</italic>). <italic>n</italic> =
3–6 (healthy volunteers); <italic>n</italic> = 1 (patient S).</p>
                  </caption>
                  <graphic xlink:href="fasebj275065f4"/>
                </fig>
              </sec>
              <sec id="s16">
                <title>Role of cPLA<sub>2</sub>α in inflammatory responses in endothelial cells
and blood leukocytes</title>
                <p>Whole blood from healthy volunteers treated with FSL-1, Poly(I:C), or LPS, but not
with IL-1β, released the inflammatory chemokine CXCL8 (<xref ref-type="fig" rid="F5"><bold>Fig. 5<italic>A</italic></bold></xref>). Blood from a
cPLA<sub>2</sub>α-deficient patient exhibited more than 5-fold greater
responses to all agents except IL-1β as compared with matched controls (<xref ref-type="fig" rid="F5">Fig. 5<italic>A</italic></xref>). Treatment of blood from
healthy volunteers with the COX inhibitor diclofenac suppressed the CXCL8 response to
LPS but did not modify CXCL8 release stimulated by other tested agents (<xref ref-type="fig" rid="F5">Fig. 5<italic>A</italic></xref>).</p>
                <fig id="F5" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 5.</label>
                  <caption>
                    <p>Effect of cPLA<sub>2</sub>α deficiency on blood leukocyte and
endothelial cell inflammatory responses. <italic>A</italic>) CXCL8 release in
whole blood from healthy volunteers with or without pretreatment with the COX
inhibitor diclofenac (Diclo; 10 μM) or a
cPLA<sub>2</sub>α-deficient patient in response to agonists to TLR2/1
(Pam3CSK4; 1 μg/ml), TLR2/6 (FSL-1; 1 μg/ml), TLR3 [poly(I:C); 10
μg/ml], TLR4 (LPS; 1 μg/ml), or IL-1 receptor (IL-1β; 1
ng/ml). <italic>B</italic>) CXCL8 release by endothelial cells to agonists of
TLR2 [heat-killed <italic>L. monocytogenes</italic> (HKLM); 10<sup>7</sup>
cells/ml], TLR2/1 (Pam3CSK4; 1 μg/ml), TLR2/6 (FSL-1; 1 μg/ml),
TLR3 [poly(I:C); 10 μg/ml], TLR4 (LPS; 10 μg/ml), TLR5 (FLA; 100
ng/ml), TLR7 (imiquimod; 1 μg/ml), TLR8 [single-stranded RNA
oligonucleotide-40 (ssRNA40); 1 μg/ml], TLR9 [oligodeoxynucleotide-2006
(ODN2006); 5 μM], or IL-1 receptor (IL-1β; 1 ng/ml).
<italic>n</italic> = 3–6 (healthy volunteers; 2 determinations each);
<italic>n</italic> = 1 (patient S; 3 determinations each).
*<italic>P</italic> &lt; 0.05 by 2-way ANOVA with
Dunnett’s posttest.</p>
                  </caption>
                  <graphic xlink:href="fasebj275065f5"/>
                </fig>
                <p>Endothelial cells from healthy donors also released CXCL8 when stimulated with
pathogen-associated molecular patterns (PAMPs) directed at TLR2, 3, or 4, or with
IL-1β. Again, as with leukocytes in whole blood, endothelial cells from a
cPLA<sub>2</sub>α-deficient patient released elevated levels of CXCL8 when
stimulated with inflammatory agents (<xref ref-type="fig" rid="F5">Fig.
5<italic>B</italic></xref>). Endothelial cells from either type of donor did
not respond to ligands for TLR5, TLR7, or TLR8 (<xref ref-type="fig" rid="F5">Fig.
5<italic>B</italic></xref>).</p>
              </sec>
              <sec id="s17">
                <title>Involvement of cPLA<sub>2</sub>α in plasma and urinary eicosanoid
levels</title>
                <p>Plasma from healthy volunteers contained primarily metabolites of linoleic acid,
eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Patients lacking
cPLA<sub>2</sub>α had reduced levels of these mediators compared with
plasma from healthy volunteers (<xref ref-type="fig" rid="F6"><bold>Fig.
6<italic>A</italic></bold></xref>). Basal plasma also contained substantial
levels of 12-HETE, and this remained in cPLA<sub>2</sub>α-deficient patient
plasma.</p>
                <fig id="F6" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 6.</label>
                  <caption>
                    <p>Contribution of cPLA<sub>2</sub>α to basal plasma and urinary eicosanoid
levels. <italic>A</italic>) Basal eicosanoid levels in plasma from healthy
volunteers (circles) or from a patient lacking cPLA<sub>2</sub>α.
<italic>n</italic> = 8 (healthy volunteers; 2 determinations each);
<italic>n</italic> = 2 (patient B and patient S; 2 determinations each).
Urinary levels of LTE<sub>4</sub> (<italic>B</italic>) and metabolites of
prostacyclin (PGI-M) (<italic>C</italic>), 8-isoprostane (8iso-M)
(<italic>D</italic>), TXA<sub>2</sub> (TX-M) (<italic>E</italic>),
PGD<sub>2</sub> [tetranor (tn)PGD-M] (<italic>F</italic>), and
PGE<sub>2</sub> (PGE-M) (<italic>G</italic>) in healthy volunteers (filled
columns) or from patients lacking cPLA<sub>2</sub>α (unfilled columns).
<italic>n</italic> = 7 (healthy volunteers; 2 determinations each);
<italic>n</italic> = 2 (patient B and patient S; 4 determinations each).</p>
                  </caption>
                  <graphic xlink:href="fasebj275065f6"/>
                </fig>
                <p>Absence of cPLA<sub>2</sub>α was associated with strong reductions in the
levels of leukotriene E4 (LTE<sub>4</sub>) and prostacyclin metabolites (<xref ref-type="fig" rid="F6">Fig. 6<italic>B</italic>, <italic>C</italic></xref>),
whereas substantial levels of PGD<sub>2</sub>, PGE<sub>2</sub>, and 8-isoprostane
metabolites remained (<xref ref-type="fig" rid="F6">Fig.
6<italic>D</italic>–<italic>G</italic></xref>). Levels of the urinary
metabolite of thromboxane A<sub>2</sub> (TX-M) were 50% lower in
cPLA<sub>2</sub>α-deficient patients as compared with healthy volunteers
(0.202 ± 0.010 ng/mg creatinine <italic>vs.</italic> 0.101 ± 0.017
ng/mg creatinine; <italic>P</italic> &lt; 0.01; <xref ref-type="fig" rid="F6">Fig. 6<italic>E</italic></xref>). In addition, substantial levels of
PGD<sub>2</sub>, PGE<sub>2</sub>, and 8-isoprostane metabolites remained in urine
samples from cPLA<sub>2</sub>α-deficient patients.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s18">
              <title>DISCUSSION</title>
              <p>Here, we have examined the contribution of cPLA<sub>2</sub>α to eicosanoid
formation, and thrombotic and inflammatory responses in platelets, blood leukocytes, and
endothelial cells from 2 individuals with a unique genetic inactivation of this enzyme.
Although we (<xref rid="B18" ref-type="bibr">18</xref>) and others (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>) have
published reports of individuals lacking functional cPLA<sub>2</sub>α, including
limited analysis of platelet responses, this is the first time a full and systematic
eicosanoid analysis has been undertaken on samples from these patients and considered in
the context of the circulatory system in health and inflammation. These data demonstrate
an absolute requirement for cPLA<sub>2</sub>α in eicosanoid synthesis in the
vascular compartment with a consequent loss of platelet activation pathways, reduced
antithrombotic prostacyclin, and increased inflammatory sensitivity of both endothelial
cells and leukocytes.</p>
              <sec id="s19">
                <title>Platelets</title>
                <p>The PLA<sub>2</sub> system in platelets is among the most clearly defined in
cardiovascular cell types. We and others have previously performed limited
phenotyping of platelets from cPLA<sub>2</sub>α-deficient individuals and
found a requirement for this enzyme in TXA<sub>2</sub> formation and collagen-induced
platelet aggregation, which is TXA<sub>2</sub> dependent. However, in addition to
cPLA<sub>2</sub>α, platelets also express sPLA<sub>2,</sub> which others
suggest contributes to eicosanoid formation in platelets (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Here, for the first time, we have performed
a full eicosanomic analysis of samples from cPLA<sub>2</sub>α-deficient
individuals to consider the role of this enzyme in synthesis of a range of functional
distinct arachidonic acid–derived mediators. Stimulation of whole blood with
the platelet activators collagen or TRAP-6 resulted in greatly increased synthesis of
TXA<sub>2</sub>, in addition to PGE<sub>2</sub>, PGD<sub>2</sub>, and 11-, 12-,
and 15-HETE, mediators primarily produced by COX and LOX pathways. 12-HETE levels
were somewhat lower in TRAP-6–stimulated blood as compared to
collagen-stimulated blood, consistent with reports that 12-LOX activation is linked
to the platelet collagen receptor, glycoprotein VI (<xref rid="B7" ref-type="bibr">7</xref>). Stimulation of blood with the receptor-independent activator
Ca<sup>2+</sup> ionophore A23187 produced a similar platelet eicosanoid
fingerprint, but unlike collagen and TRAP-6, increased levels of 5-HETE, reflecting
acute activation of leukocytes. In each case, eicosanoid production was
cPLA<sub>2</sub>α dependent because it was lost in
cPLA<sub>2</sub>α-deficient patient blood but reversed by the addition of
exogenous arachidonic acid, demonstrating its dependence on loss of endogenous
substrate release. In agreement, isolated cPLA<sub>2</sub>α-deficient
platelets stimulated with a range of agonists (collagen, ADP, and U46619), but not
exogenous arachidonic acid, exhibited a complete loss of TXA<sub>2</sub> synthesis,
in contrast to reports that ADP-induced release is not altered in
cPLA<sub>2</sub>α-knockout mouse platelets (<xref rid="B9" ref-type="bibr">9</xref>). These data illustrate the requirement for cPLA<sub>2</sub>α in
the full range of eicosanoids synthesized by platelets and that this is independent
of the stimulus used (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>).</p>
                <p>We next set out to establish the contribution of cPLA<sub>2</sub>α-derived
eicosanoids to functional platelet aggregation responses. Although it is well known
that the platelet COX product TXA<sub>2</sub> is a powerful proaggregatory agent,
this response may be modified by other eicosanoid mediators synthesized in parallel.
Indeed, PGE<sub>2</sub> (<xref rid="B31" ref-type="bibr">31</xref>), 12-HETE (<xref rid="B32" ref-type="bibr">32</xref><xref rid="B33" ref-type="bibr"/>–<xref rid="B34" ref-type="bibr">34</xref>), 15-HETE (<xref rid="B35" ref-type="bibr">35</xref>), and 5,6-EET (<xref rid="B36" ref-type="bibr">36</xref>) increase
platelet activation, whereas PGD<sub>2</sub> (<xref rid="B37" ref-type="bibr">37</xref>) and higher levels of PGE<sub>2</sub> may limit platelet activation
(<xref rid="B31" ref-type="bibr">31</xref>), meaning the net contribution of
cPLA<sub>2</sub>α-derived eicosanoids is unclear. Our studies using
traditional light transmission lumi-aggregometry and 96-well plate aggregometry
demonstrated that inhibition or absence of cPLA<sub>2</sub>α produced a marked
reduction in collagen-induced platelet aggregation and dense granule (ATP) secretion,
in agreement with what we (<xref rid="B18" ref-type="bibr">18</xref>) and others
(<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>) have previously reported.
These defects were rescued by exogenous arachidonic acid, demonstrating that they
were specifically associated with loss of endogenous substrate release. Similarly,
platelet adhesion to a collagen-coated surface in flowing blood was abolished by
cPLA<sub>2</sub> inhibition and absent in blood from
cPLA<sub>2</sub>α-deficient patients. These data are in agreement with reports
of the importance of cPLA<sub>2</sub>α and TXA<sub>2</sub> generation in
platelet adhesion (<xref rid="B38" ref-type="bibr">38</xref>). In each of these
functional assays, the reduction observed was similar to that produced by the COX
inhibitor aspirin, suggesting that regulation of collagen-induced platelet responses
by cPLA<sub>2</sub>α is due to products of platelet COX-1, probably
TXA<sub>2</sub>. Overall, these data show that cPLA<sub>2</sub>α is
absolutely required for formation of eicosanoid mediators in platelets and that
despite the synthesis of several eicosanoid families, the contribution of
cPLA<sub>2</sub>α to platelet aggregation, secretion, and adhesion
responses can be entirely accounted for by generation of COX products. This reduction
in platelet function is consistent with an increased tendency to bruising noted in
the clinical care of these patients.</p>
              </sec>
              <sec id="s20">
                <title>Endothelium</title>
                <p>Through eicosanoid release, endothelial cells are key to health and disease of the
circulation. Here, we have made use of endothelial cells isolated from blood
progenitors providing the first opportunity to study genetic deficiency of
cPLA<sub>2</sub>α in human endothelium. Endothelial cells from a
cPLA<sub>2</sub>α-deficient patient expressed the normal endothelial cell
markers CD31 and vascular endothelial-cadherin, had a cobblestone morphology, and
when cultured under conditions of chronic (3 d) laminar shear stress (<xref rid="B29" ref-type="bibr">29</xref>), aligned with the direction of shear,
demonstrating their endothelial phenotype. When we examined eicosanoid production by
endothelial cells, A23187 stimulation increased production of several eicosanoid
mediators, the most abundant of which was prostacyclin, with lower levels of
PGE<sub>2</sub>, PGD<sub>2</sub>, and 11-, 12-, and 15-HETE. These were
predominantly driven by cPLA<sub>2</sub>α because they were strongly reduced
in cPLA<sub>2</sub>α-deficient endothelial cells. This was further confirmed
by the ability of a selective cPLA<sub>2</sub> inhibitor to prevent the majority of
A23187-stimulated prostacyclin production by endothelial cells and was specific
because cPLA<sub>2</sub>α-deficient endothelial cells responded normally to
exogenous arachidonic acid. However, cPLA<sub>2</sub>α-deficient endothelial
cells stimulated with either A23187 or thrombin continued to produce some
prostacyclin, probably reflecting contribution of other PLA<sub>2</sub> isoforms
[<italic>e.g.</italic>, group VIA iPLA<sub>2</sub> (also referred to as
iPLA<sub>2</sub>β)] to eicosanoid generation in endothelium (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>).</p>
              </sec>
              <sec id="s21">
                <title>Leukocytes and inflammation</title>
                <p>In parallel with platelet and endothelial cell studies, we examined the effect of
addition of inflammatory stimuli (<italic>e.g.</italic>, LPS) to whole blood to
investigate the role of cPLA<sub>2</sub>α in blood leukocyte responses, an
approach frequently applied in the eicosanoid field (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B39" ref-type="bibr">39</xref>). When whole blood was
stimulated with A23187, in addition to platelet-derived mediators, 5-HETE was
detected, which is associated with 5-LOX present in monocytes and neutrophils (<xref rid="B40" ref-type="bibr">40</xref>). When blood was stimulated with LPS to
specifically activate leukocytes and inducible biosynthetic pathways such as COX-2, a
more characteristic inflammatory eicosanoid profile was produced with
PGE<sub>2</sub>, 12- and 15-HETE being the most abundant products. In each case,
eicosanoid synthesis was cPLA<sub>2</sub>α mediated. In
cPLA<sub>2</sub>α-deficient patient blood, LPS-induced production of
PGE<sub>2</sub> and 15-HETE was greatly reduced, and overall, productions were
restored by acute addition of arachidonic acid, confirming that this defect is due to
loss of free endogenous arachidonic acid. In contrast, in LPS-stimulated blood, the
production of 12-HETE was little affected by cPLA<sub>2</sub>α deficiency,
suggesting that other PLA<sub>2</sub> isoforms specifically couple to 12-HETE
synthesis in blood leukocytes. By its actions on TLR4, LPS mimics the effects of
gram-negative bacteria. However, other pathogens activate immune and inflammatory
responses in tissues through different pattern recognition receptor signaling
pathways, each of which could theoretically drive eicosanoid production by different
PLA<sub>2</sub> isoforms. To address this, we studied the effect of a full range
of PAMPs that mimic gram-positive, as well as gram-negative, bacteria or viruses.
Thus, Pam3CSK4 (TLR2/1) and FSL-1 (TLR2/6), which activate pattern recognition
receptors associated with gram-positive bacteria, as with LPS, activated whole blood
to release PGE<sub>2</sub>, an effect that was abolished by cPLA<sub>2</sub>α
deficiency. Neither Poly(I:C), which stimulates the viral pathogen recognition
receptor TLR3, nor IL-1β, which works independently of pattern recognition
receptors, stimulated PGE<sub>2</sub> release from whole blood. Although these data
demonstrate that cPLA<sub>2</sub>α is central to leukocyte eicosanoid
synthesis, particularly for PGE<sub>2</sub>, there are clearly roles for other
PLA<sub>2</sub> isoforms such as sPLA<sub>2</sub> (<xref rid="B13" ref-type="bibr">13</xref>).</p>
                <p>To understand the implications of loss of eicosanoid production to the inflammatory
response, we measured CXCL8 production, induction of which reflects both primary
activation of inflammatory transcriptional pathways such as NF-κB pathways and
subsequent secretion of TNF-α and IL-1β (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B41" ref-type="bibr">41</xref>). Whole blood from
healthy volunteers treated with FSL-1, Poly(I:C), or LPS, but not with IL-1β,
released the inflammatory chemokine CXCL8. Blood from a
cPLA<sub>2</sub>α-deficient patient exhibited more than 5-fold greater
responses to all agents except IL-1β as compared with matched controls (<xref ref-type="fig" rid="F5">Fig. 5<italic>A</italic></xref>). Treatment of blood from
healthy volunteers with the COX inhibitor diclofenac suppressed the CXCL8 response to
LPS but did not modify CXCL8 release stimulated by other tested agents (<xref ref-type="fig" rid="F5">Fig. 5<italic>A</italic></xref>), indicating that the
effect was not mediated by loss of COX metabolites. Although it cannot be excluded
that cPLA<sub>2</sub>α-deficient patient blood contains altered leukocyte
subsets, blood constituents, or other confounding influences, these data suggest that
cPLA<sub>2</sub>α-dependent mediators, other than COX products, act to
suppress cytokine responses by blood leukocytes. This effect may reflect loss of 11-
and/or 15-HETE synthesis because these were also detected in LPS-stimulated whole
blood, and it has been previously reported that 15-HETE has anti-inflammatory
activity (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>).</p>
                <p>Similarly, endothelial cells from healthy donors released CXCL8 when stimulated with
PAMPs directed at TLR2, 3, or 4, or with IL-1β. As with leukocytes in whole
blood, endothelial cells from a cPLA<sub>2</sub>α-deficient patient released
elevated levels of CXCL8 when stimulated with inflammatory agents, consistent with
activation of NF-κB pathways following treatment with inflammatory stimuli, as
we have previously described (<xref rid="B25" ref-type="bibr">25</xref>). Endothelial
cells from either type of donor did not respond to ligands for TLR5, the pattern
recognition receptor for motile bacteria and fungi, TLR7 and TLR8, pattern
recognition receptors for single-stranded RNA viruses, or TLR9, which is the pattern
recognition receptor for bacterial DNA. Importantly, in contrast to blood leukocyte
studies, these endothelial cells constitute a single, defined cell type in a
controlled medium suggesting that any differences observed likely reflect changes in
eicosanoid production as compared to confounding factors present in blood cells.
Because prostacyclin was the most abundant eicosanoid produced by endothelial cells
and is a powerful inhibitor of vascular inflammation, this proinflammatory phenotype
of cPLA<sub>2</sub>α-deficient endothelial cells is most easily explained by
loss of this fundamental vascular hormone. CXCL8 is a potent neutrophil chemotactic
factor, which has been implicated in atherogenesis (<xref rid="B44" ref-type="bibr">44</xref>); thus, augmented production of CXCL8 and potentially other
NF-κB–driven cytokines is likely to be detrimental to cardiovascular
health. Moreover, taken together, these studies demonstrate that on a global level,
blood leukocytes and endothelial cells require cPLA<sub>2</sub>α to produce
eicosanoids in response to a range of inflammatory stimuli, and this exerts both
COX-dependent and possibly COX-independent regulation of cytokine production and, by
inference, immunologic/inflammatory defenses, consistent with clinical manifestations
in these patients (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>).</p>
              </sec>
              <sec id="s22">
                <title>Production <italic>in vivo</italic></title>
                <p>Finally, to provide an overview of the contribution of cPLA<sub>2</sub>α to
eicosanoid formation from all sources in the body, we measured the eicosanoid profile
in plasma and specific urinary eicosanoid metabolites. Plasma from healthy volunteers
contained low levels of primarily metabolites of linoleic acid, EPA, and DHA.
Patients lacking cPLA<sub>2</sub>α had reduced levels of these mediators
compared with plasma from healthy volunteers. Because cPLA<sub>2</sub>α has
strong specificity for arachidonate-containing phospholipids, this may reflect
altered physiology in these patients. Notably, basal plasma also contained
substantial levels of 12-HETE, which may reflect platelet activation during blood
sampling; as noted above, 12-HETE is the major product of activated platelets.
However, surprisingly, a small 12-HETE peak was also seen in
cPLA<sub>2</sub>α-deficient patient plasma, suggesting possible
cPLA<sub>2</sub>α-independent eicosanoid formation in the body.</p>
                <p>Interpretation of plasma eicosanoid data as representative of a circulating pool is
difficult because levels may reflect local vascular activation during blood sampling,
and many eicosanoids rapidly degrade/clear from the circulation. For this reason,
many favor measurement of urinary metabolites to assess <italic>in vivo</italic>
eicosanoid production. Using this approach, we observed that absence of
cPLA<sub>2</sub>α was associated with strong reductions in the levels of
LTE<sub>4</sub>, prostacyclin, and TXA<sub>2</sub> metabolites, consistent with
the reductions in TXA<sub>2</sub> production by platelets, prostacyclin production by
endothelial cells, and 5-HETE production by monocytes/neutrophils [LTE<sub>4</sub> is
a downstream metabolite of 5-LOX products (<xref rid="B40" ref-type="bibr">40</xref>)] that we noted in our <italic>in vitro</italic> cell studies. Of
particular relevance to platelet function was the urinary TXA<sub>2</sub> metabolite,
TX-M. This has been often recommended as a marker of platelet activation <italic>in
vivo</italic> that could be used to gauge the efficacy of aspirin treatment and
the level of ongoing platelet activation (<xref rid="B45" ref-type="bibr">45</xref>).
We noted that whereas platelets from cPLA<sub>2</sub>α-deficient patients did
not produce TXA<sub>2</sub>, urinary levels of TX-M in the patients were reduced only
by ∼50%. This demonstrates that urinary TX-M does not specifically report
production from platelets and adds to a growing body of evidence questioning the
origin of TX-M and other urinary prostanoid metabolites (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B46" ref-type="bibr">46</xref>). In addition,
substantial levels of PGD<sub>2</sub>, PGE<sub>2</sub>, and 8-isoprostane metabolites
remained in urine samples from cPLA<sub>2</sub>α-deficient patients, further
suggesting that there are sites in the body where considerable
cPLA<sub>2</sub>α-independent prostanoid formation occurs.</p>
              </sec>
            </sec>
            <sec id="s23">
              <title>CONCLUSIONS</title>
              <p>Here, we have examined the contribution of cPLA<sub>2</sub>α to eicosanoid
formation, and thrombotic and inflammatory responses in platelets, blood leukocytes, and
endothelial cells from individuals with a unique genetic inactivation of this enzyme.
Our data demonstrate an absolute requirement for cPLA<sub>2</sub>α in eicosanoid
synthesis in the vascular compartment with a consequent loss of platelet activation
pathways, reduced antithrombotic prostacyclin, and increased inflammatory sensitivity of
both endothelial cells and leukocytes. This study unites many conflicting observations
in the literature and provides a definitive account of the rate-limiting and perhaps
most fundamental component of this system, cPLA<sub>2</sub>α.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="PMC_1" content-type="local-data">
                <caption>
                  <title>Supplemental Data</title>
                </caption>
                <media mimetype="text" mime-subtype="html" xlink:href="supp_29_11_4568__index.html"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_fj.15-275065_Supplemental_Figures.pdf"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_fj.15-275065_Supplemental_Table1.pdf"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_fj.15-275065_Supplemental_Table2.pdf"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_fj.15-275065_Supplemental_Table3.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn id="FN1" fn-type="supplementary-material">
                <p>This article includes supplemental data. Please visit <italic><ext-link ext-link-type="uri" xlink:href="http://www.fasebj.org">http://www.fasebj.org</ext-link></italic> to obtain this information.</p>
              </fn>
            </fn-group>
            <ack>
              <title>ACKNOWLEDGMENTS</title>
              <p>The authors acknowledge the cytosolic phospholipase A<sub>2</sub>-deficient individuals
who made these studies possible by volunteering to provide blood samples. This research
was supported by an Imperial College Junior Research Fellowship (to N.S.K.), Wellcome
Trust program grant (0852551Z108/Z to J.A.M. and T.D.W.), British Heart Foundation Ph.D.
studentship (FS/10/033/28271 to F.R.), British Heart Foundation project grant
(PG/11/39/28890 to D.B.-B.), and by the Intramural Research Program of the U.S. National
Institutes of Health, National Institute of Environmental Health Sciences (Z01 ES025034
to D.C.Z.).</p>
            </ack>
            <glossary>
              <def-list list-type="simple" list-content="abbreviations">
                <def-item>
                  <term id="G1">CD31</term>
                  <def>
                    <p>platelet endothelial cell adhesion molecule-1</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G2">COX</term>
                  <def>
                    <p>cyclooxygenase</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G3">cPLA<sub>2</sub></term>
                  <def>
                    <p>cytosolic phospholipase A<sub>2</sub></p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G4">CXCL8</term>
                  <def>
                    <p>(C-X-C motif) ligand-8</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G5">DHA</term>
                  <def>
                    <p>docosahexaenoic acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G6">EET</term>
                  <def>
                    <p>epoxyeicosatrienoic acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G7">EPA</term>
                  <def>
                    <p>eicosapentaenoic acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G8">FLA</term>
                  <def>
                    <p>flagellin</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G9">FSL-1</term>
                  <def>
                    <p>bisacylated lipoprotein CGDPKHPKSF</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G10">HETE</term>
                  <def>
                    <p>hydroxyeicosatetraenoic acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G11">iPLA<sub>2</sub></term>
                  <def>
                    <p>calcium-independent phospholipase A<sub>2</sub></p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G12">LOX</term>
                  <def>
                    <p>lipoxygenase</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G13">LTE<sub>4</sub></term>
                  <def>
                    <p>leukotriene E4</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G14">Pam3CSK4</term>
                  <def>
                    <p>triacylated lipoprotein CSK4</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G15">PAMP</term>
                  <def>
                    <p>pathogen-associated molecular pattern</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G16">PGD<sub>2</sub></term>
                  <def>
                    <p>prostaglandin D<sub>2</sub></p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G17">PGE<sub>2</sub></term>
                  <def>
                    <p>prostaglandin E<sub>2</sub></p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G18">PLA<sub>2</sub></term>
                  <def>
                    <p>phospholipase A<sub>2</sub></p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G19">Poly(I:C)</term>
                  <def>
                    <p>polyinosinic:polycytidylic acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G20">prostacyclin</term>
                  <def>
                    <p>prostaglandin I<sub>2</sub></p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G21">sPLA<sub>2</sub></term>
                  <def>
                    <p>secreted phospholipase A<sub>2</sub></p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G22">TRAP</term>
                  <def>
                    <p>thrombin receptor-activating peptide</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G23">TXA<sub>2</sub></term>
                  <def>
                    <p>thromboxane A<sub>2</sub></p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G24">TX-M</term>
                  <def>
                    <p>metabolite of thromboxane A<sub>2</sub></p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warner</surname><given-names>T.
D.</given-names></name>, <name name-style="western"><surname>Nylander</surname><given-names>S.</given-names></name>,
<name name-style="western"><surname>Whatling</surname><given-names>C.</given-names></name></person-group> (<year>2011</year>)
<article-title>Anti-platelet therapy: cyclo-oxygenase inhibition and the use of
aspirin with particular regard to dual anti-platelet therapy.</article-title>
<source>Br. J. Clin. Pharmacol.</source>
<volume>72</volume>, <fpage>619</fpage>–<lpage>633</lpage>
<pub-id pub-id-type="pmid">21320154</pub-id></mixed-citation>
              </ref>
              <ref id="B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>J.
A.</given-names></name>, <name name-style="western"><surname>Warner</surname><given-names>T. D.</given-names></name></person-group>
(<year>2006</year>) <article-title>COX isoforms in the cardiovascular system:
understanding the activities of non-steroidal anti-inflammatory
drugs.</article-title>
<source>Nat. Rev. Drug Discov.</source>
<volume>5</volume>, <fpage>75</fpage>–<lpage>86</lpage>
<pub-id pub-id-type="pmid">16485347</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warner</surname><given-names>T.
D.</given-names></name>, <name name-style="western"><surname>Giuliano</surname><given-names>F.</given-names></name>,
<name name-style="western"><surname>Vojnovic</surname><given-names>I.</given-names></name>,
<name name-style="western"><surname>Bukasa</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Mitchell</surname><given-names>J.
A.</given-names></name>, <name name-style="western"><surname>Vane</surname><given-names>J. R.</given-names></name></person-group>
(<year>1999</year>) <article-title>Nonsteroid drug selectivities for
cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human
gastrointestinal toxicity: a full in vitro analysis.</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<volume>96</volume>, <fpage>7563</fpage>–<lpage>7568</lpage>
<pub-id pub-id-type="pmid">10377455</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murakami</surname><given-names>M.</given-names></name>,
<name name-style="western"><surname>Taketomi</surname><given-names>Y.</given-names></name>,
<name name-style="western"><surname>Miki</surname><given-names>Y.</given-names></name>,
<name name-style="western"><surname>Sato</surname><given-names>H.</given-names></name>,
<name name-style="western"><surname>Hirabayashi</surname><given-names>T.</given-names></name>,
<name name-style="western"><surname>Yamamoto</surname><given-names>K.</given-names></name></person-group> (<year>2011</year>)
<article-title>Recent progress in phospholipase A₂ research: from cells to
animals to humans.</article-title>
<source>Prog. Lipid Res.</source>
<volume>50</volume>, <fpage>152</fpage>–<lpage>192</lpage>
<pub-id pub-id-type="pmid">21185866</pub-id></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burke</surname><given-names>J.
E.</given-names></name>, <name name-style="western"><surname>Dennis</surname><given-names>E. A.</given-names></name></person-group>
(<year>2009</year>) <article-title>Phospholipase A2 structure/function, mechanism,
and signaling.</article-title>
<source>J. Lipid Res.</source>
<volume>50</volume> (<issue>Suppl</issue>),
<fpage>S237</fpage>–<lpage>S242</lpage>
<pub-id pub-id-type="pmid">19011112</pub-id></mixed-citation>
              </ref>
              <ref id="B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polgár</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Kramer</surname><given-names>R.
M.</given-names></name>, <name name-style="western"><surname>Um</surname><given-names>S. L.</given-names></name>,
<name name-style="western"><surname>Jakubowski</surname><given-names>J.
A.</given-names></name>, <name name-style="western"><surname>Clemetson</surname><given-names>K. J.</given-names></name></person-group>
(<year>1997</year>) <article-title>Human group II 14 kDa phospholipase A2
activates human platelets.</article-title>
<source>Biochem. J.</source>
<volume>327</volume>, <fpage>259</fpage>–<lpage>265</lpage><pub-id pub-id-type="pmid">9355761</pub-id></mixed-citation>
              </ref>
              <ref id="B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffey</surname><given-names>M.
J.</given-names></name>, <name name-style="western"><surname>Jarvis</surname><given-names>G. E.</given-names></name>,
<name name-style="western"><surname>Gibbins</surname><given-names>J.
M.</given-names></name>, <name name-style="western"><surname>Coles</surname><given-names>B.</given-names></name>,
<name name-style="western"><surname>Barrett</surname><given-names>N.
E.</given-names></name>, <name name-style="western"><surname>Wylie</surname><given-names>O. R.</given-names></name>,
<name name-style="western"><surname>O’Donnell</surname><given-names>V.
B.</given-names></name></person-group> (<year>2004</year>)
<article-title>Platelet 12-lipoxygenase activation via glycoprotein VI:
involvement of multiple signaling pathways in agonist control of H(P)ETE
synthesis.</article-title>
<source>Circ. Res.</source>
<volume>94</volume>, <fpage>1598</fpage>–<lpage>1605</lpage>
<pub-id pub-id-type="pmid">15142951</pub-id></mixed-citation>
              </ref>
              <ref id="B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Houliston</surname><given-names>R.
A.</given-names></name>, <name name-style="western"><surname>Wheeler-Jones</surname><given-names>C. P.</given-names></name></person-group>
(<year>2001</year>) <article-title>sPLA(2) cooperates with cPLA(2)alpha to
regulate prostacyclin synthesis in human endothelial cells.</article-title>
<source>Biochem. Biophys. Res. Commun.</source>
<volume>287</volume>, <fpage>881</fpage>–<lpage>887</lpage>
<pub-id pub-id-type="pmid">11573947</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>D.
A.</given-names></name>, <name name-style="western"><surname>Kita</surname><given-names>Y.</given-names></name>,
<name name-style="western"><surname>Uozumi</surname><given-names>N.</given-names></name>,
<name name-style="western"><surname>Shimizu</surname><given-names>T.</given-names></name></person-group> (<year>2002</year>)
<article-title>Discrete role for cytosolic phospholipase A(2)alpha in platelets:
studies using single and double mutant mice of cytosolic and group IIA secretory
phospholipase A(2).</article-title>
<source>J. Exp. Med.</source>
<volume>196</volume>, <fpage>349</fpage>–<lpage>357</lpage>
<pub-id pub-id-type="pmid">12163563</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blache</surname><given-names>D.</given-names></name>,
<name name-style="western"><surname>Gautier</surname><given-names>T.</given-names></name>,
<name name-style="western"><surname>Tietge</surname><given-names>U.
J.</given-names></name>, <name name-style="western"><surname>Lagrost</surname><given-names>L.</given-names></name></person-group>
(<year>2012</year>) <article-title>Activated platelets contribute to oxidized
low-density lipoproteins and dysfunctional high-density lipoproteins through a
phospholipase A2-dependent mechanism.</article-title>
<source>FASEB J.</source>
<volume>26</volume>, <fpage>927</fpage>–<lpage>937</lpage><pub-id pub-id-type="pmid">22042222</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Turk</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>McHowat</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>)
<article-title>Endothelial cell prostaglandin I(2) and platelet-activating factor
production are markedly attenuated in the calcium-independent phospholipase
A(2)beta knockout mouse.</article-title>
<source>Biochemistry</source>
<volume>49</volume>, <fpage>5473</fpage>–<lpage>5481</lpage>
<pub-id pub-id-type="pmid">20521843</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>M.
S.</given-names></name>, <name name-style="western"><surname>Man</surname><given-names>R. Y.</given-names></name>,
<name name-style="western"><surname>Vanhoutte</surname><given-names>P.
M.</given-names></name></person-group> (<year>2010</year>)
<article-title>Calcium-independent phospholipase A(2) plays a key role in the
endothelium-dependent contractions to acetylcholine in the aorta of the
spontaneously hypertensive rat.</article-title>
<source>Am. J. Physiol. Heart Circ. Physiol.</source>
<volume>298</volume>, <fpage>H1260</fpage>–<lpage>H1266</lpage>
<pub-id pub-id-type="pmid">20118407</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Krump</surname><given-names>E.</given-names></name>,
<name name-style="western"><surname>Lindsay</surname><given-names>T.</given-names></name>,
<name name-style="western"><surname>Downey</surname><given-names>G.</given-names></name>,
<name name-style="western"><surname>Ford</surname><given-names>D.
A.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>P.</given-names></name>,
<name name-style="western"><surname>Walker</surname><given-names>P.</given-names></name>,
<name name-style="western"><surname>Rubin</surname><given-names>B.</given-names></name></person-group> (<year>2000</year>)
<article-title>Involvement of cytosolic phospholipase A2 and secretory
phospholipase A2 in arachidonic acid release from human
neutrophils.</article-title>
<source>J. Immunol.</source>
<volume>164</volume>, <fpage>2084</fpage>–<lpage>2091</lpage>
<pub-id pub-id-type="pmid">10657662</pub-id></mixed-citation>
              </ref>
              <ref id="B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balsinde</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Dennis</surname><given-names>E.
A.</given-names></name></person-group> (<year>1996</year>)
<article-title>Distinct roles in signal transduction for each of the phospholipase
A2 enzymes present in P388D1 macrophages.</article-title>
<source>J. Biol. Chem.</source>
<volume>271</volume>, <fpage>6758</fpage>–<lpage>6765</lpage>
<pub-id pub-id-type="pmid">8636097</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicholls</surname><given-names>S.
J.</given-names></name>, <name name-style="western"><surname>Kastelein</surname><given-names>J. J.</given-names></name>,
<name name-style="western"><surname>Schwartz</surname><given-names>G.
G.</given-names></name>, <name name-style="western"><surname>Bash</surname><given-names>D.</given-names></name>,
<name name-style="western"><surname>Rosenson</surname><given-names>R.
S.</given-names></name>, <name name-style="western"><surname>Cavender</surname><given-names>M. A.</given-names></name>,
<name name-style="western"><surname>Brennan</surname><given-names>D.
M.</given-names></name>, <name name-style="western"><surname>Koenig</surname><given-names>W.</given-names></name>,
<name name-style="western"><surname>Jukema</surname><given-names>J.
W.</given-names></name>, <name name-style="western"><surname>Nambi</surname><given-names>V.</given-names></name>,
<name name-style="western"><surname>Wright</surname><given-names>R.
S.</given-names></name>, <name name-style="western"><surname>Menon</surname><given-names>V.</given-names></name>,
<name name-style="western"><surname>Lincoff</surname><given-names>A.
M.</given-names></name>, <name name-style="western"><surname>Nissen</surname><given-names>S. E.</given-names></name>; <collab>VISTA-16
Investigators</collab></person-group> (<year>2014</year>)
<article-title>Varespladib and cardiovascular events in patients with an acute
coronary syndrome: the VISTA-16 randomized clinical trial.</article-title>
<source>JAMA</source>
<volume>311</volume>, <fpage>252</fpage>–<lpage>262</lpage>
<pub-id pub-id-type="pmid">24247616</pub-id></mixed-citation>
              </ref>
              <ref id="B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riendeau</surname><given-names>D.</given-names></name>,
<name name-style="western"><surname>Guay</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Weech</surname><given-names>P.
K.</given-names></name>,
<name name-style="western"><surname>Laliberté</surname><given-names>F.</given-names></name>,
<name name-style="western"><surname>Yergey</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>,
<name name-style="western"><surname>Desmarais</surname><given-names>S.</given-names></name>,
<name name-style="western"><surname>Perrier</surname><given-names>H.</given-names></name>,
<name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name>,
<name name-style="western"><surname>Nicoll-Griffith</surname><given-names>D.</given-names></name></person-group>
(<year>1994</year>) <article-title>Arachidonyl trifluoromethyl ketone, a potent
inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and
12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged
platelets.</article-title>
<source>J. Biol. Chem.</source>
<volume>269</volume>,
<fpage>15619</fpage>–<lpage>15624</lpage><pub-id pub-id-type="pmid">8195210</pub-id></mixed-citation>
              </ref>
              <ref id="B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartoli</surname><given-names>F.</given-names></name>,
<name name-style="western"><surname>Lin</surname><given-names>H.
K.</given-names></name>, <name name-style="western"><surname>Ghomashchi</surname><given-names>F.</given-names></name>,
<name name-style="western"><surname>Gelb</surname><given-names>M.
H.</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>M. K.</given-names></name>,
<name name-style="western"><surname>Apitz-Castro</surname><given-names>R.</given-names></name></person-group> (<year>1994</year>)
<article-title>Tight binding inhibitors of 85-kDa phospholipase A2 but not 14-kDa
phospholipase A2 inhibit release of free arachidonate in thrombin-stimulated human
platelets.</article-title>
<source>J. Biol. Chem.</source>
<volume>269</volume>,
<fpage>15625</fpage>–<lpage>15630</lpage><pub-id pub-id-type="pmid">8195211</pub-id></mixed-citation>
              </ref>
              <ref id="B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooke</surname><given-names>M.
A.</given-names></name>, <name name-style="western"><surname>Longhurst</surname><given-names>H. J.</given-names></name>,
<name name-style="western"><surname>Plagnol</surname><given-names>V.</given-names></name>,
<name name-style="western"><surname>Kirkby</surname><given-names>N.
S.</given-names></name>, <name name-style="western"><surname>Mitchell</surname><given-names>J. A.</given-names></name>,
<name name-style="western"><surname>Rüschendorf</surname><given-names>F.</given-names></name>,
<name name-style="western"><surname>Warner</surname><given-names>T.
D.</given-names></name>, <name name-style="western"><surname>Kelsell</surname><given-names>D. P.</given-names></name>,
<name name-style="western"><surname>MacDonald</surname><given-names>T.
T.</given-names></name></person-group> (<year>2014</year>)
<article-title>Cryptogenic multifocal ulcerating stenosing enteritis associated
with homozygous deletion mutations in cytosolic phospholipase
A2-α.</article-title>
<source>Gut</source>
<volume>63</volume>, <fpage>96</fpage>–<lpage>104</lpage>
<pub-id pub-id-type="pmid">23268370</pub-id></mixed-citation>
              </ref>
              <ref id="B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adler</surname><given-names>D.
H.</given-names></name>, <name name-style="western"><surname>Cogan</surname><given-names>J. D.</given-names></name>,
<name name-style="western"><surname>Phillips</surname><given-names>J. A.</given-names><suffix>III</suffix></name>,
<name name-style="western"><surname>Schnetz-Boutaud</surname><given-names>N.</given-names></name>,
<name name-style="western"><surname>Milne</surname><given-names>G.
L.</given-names></name>, <name name-style="western"><surname>Iverson</surname><given-names>T.</given-names></name>,
<name name-style="western"><surname>Stein</surname><given-names>J.
A.</given-names></name>, <name name-style="western"><surname>Brenner</surname><given-names>D. A.</given-names></name>,
<name name-style="western"><surname>Morrow</surname><given-names>J.
D.</given-names></name>, <name name-style="western"><surname>Boutaud</surname><given-names>O.</given-names></name>,
<name name-style="western"><surname>Oates</surname><given-names>J.
A.</given-names></name></person-group> (<year>2008</year>)
<article-title>Inherited human cPLA(2alpha) deficiency is associated with impaired
eicosanoid biosynthesis, small intestinal ulceration, and platelet
dysfunction.</article-title>
<source>J. Clin. Invest.</source>
<volume>118</volume>, <fpage>2121</fpage>–<lpage>2131</lpage><pub-id pub-id-type="pmid">18451993</pub-id></mixed-citation>
              </ref>
              <ref id="B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faioni</surname><given-names>E.
M.</given-names></name>, <name name-style="western"><surname>Razzari</surname><given-names>C.</given-names></name>,
<name name-style="western"><surname>Zulueta</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Femia</surname><given-names>E.
A.</given-names></name>, <name name-style="western"><surname>Fenu</surname><given-names>L.</given-names></name>,
<name name-style="western"><surname>Trinchera</surname><given-names>M.</given-names></name>,
<name name-style="western"><surname>Podda</surname><given-names>G.
M.</given-names></name>, <name name-style="western"><surname>Pugliano</surname><given-names>M.</given-names></name>,
<name name-style="western"><surname>Marongiu</surname><given-names>F.</given-names></name>,
<name name-style="western"><surname>Cattaneo</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>)
<article-title>Bleeding diathesis and gastro-duodenal ulcers in inherited
cytosolic phospholipase-A2 alpha deficiency.</article-title>
<source>Thromb. Haemost.</source>
<volume>112</volume>, <fpage>1182</fpage>–<lpage>1189</lpage>
<pub-id pub-id-type="pmid">25102815</pub-id></mixed-citation>
              </ref>
              <ref id="B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>J.
W.</given-names></name>, <name name-style="western"><surname>Watanabe</surname><given-names>T.</given-names></name>,
<name name-style="western"><surname>Hammock</surname><given-names>B.
D.</given-names></name></person-group> (<year>2002</year>)
<article-title>The simultaneous quantification of cytochrome P450 dependent
linoleate and arachidonate metabolites in urine by HPLC-MS/MS.</article-title>
<source>J. Lipid Res.</source>
<volume>43</volume>, <fpage>1563</fpage>–<lpage>1578</lpage>
<pub-id pub-id-type="pmid">12235189</pub-id></mixed-citation>
              </ref>
              <ref id="B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniel</surname><given-names>V.
C.</given-names></name>, <name name-style="western"><surname>Minton</surname><given-names>T. A.</given-names></name>,
<name name-style="western"><surname>Brown</surname><given-names>N.
J.</given-names></name>, <name name-style="western"><surname>Nadeau</surname><given-names>J. H.</given-names></name>,
<name name-style="western"><surname>Morrow</surname><given-names>J.
D.</given-names></name></person-group> (<year>1994</year>)
<article-title>Simplified assay for the quantification of
2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass
spectrometry.</article-title>
<source>J. Chromatogr. B Biomed. Appl.</source>
<volume>653</volume>, <fpage>117</fpage>–<lpage>122</lpage>
<pub-id pub-id-type="pmid">8205238</pub-id></mixed-citation>
              </ref>
              <ref id="B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkby</surname><given-names>N.
S.</given-names></name>, <name name-style="western"><surname>Lundberg</surname><given-names>M. H.</given-names></name>,
<name name-style="western"><surname>Harrington</surname><given-names>L.
S.</given-names></name>, <name name-style="western"><surname>Leadbeater</surname><given-names>P. D.</given-names></name>,
<name name-style="western"><surname>Milne</surname><given-names>G.
L.</given-names></name>, <name name-style="western"><surname>Potter</surname><given-names>C. M.</given-names></name>,
<name name-style="western"><surname>Al-Yamani</surname><given-names>M.</given-names></name>,
<name name-style="western"><surname>Adeyemi</surname><given-names>O.</given-names></name>,
<name name-style="western"><surname>Warner</surname><given-names>T.
D.</given-names></name>, <name name-style="western"><surname>Mitchell</surname><given-names>J. A.</given-names></name></person-group>
(<year>2012</year>) <article-title>Cyclooxygenase-1, not cyclooxygenase-2, is
responsible for physiological production of prostacyclin in the cardiovascular
system.</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<volume>109</volume>, <fpage>17597</fpage>–<lpage>17602</lpage>
<pub-id pub-id-type="pmid">23045674</pub-id></mixed-citation>
              </ref>
              <ref id="B24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin-Ramirez</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Hofman</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>van den
Biggelaar</surname><given-names>M.</given-names></name>,
<name name-style="western"><surname>Hebbel</surname><given-names>R.
P.</given-names></name>, <name name-style="western"><surname>Voorberg</surname><given-names>J.</given-names></name></person-group>
(<year>2012</year>) <article-title>Establishment of outgrowth endothelial cells
from peripheral blood.</article-title>
<source>Nat. Protoc.</source>
<volume>7</volume>, <fpage>1709</fpage>–<lpage>1715</lpage>
<pub-id pub-id-type="pmid">22918388</pub-id></mixed-citation>
              </ref>
              <ref id="B25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>D.
M.</given-names></name>, <name name-style="western"><surname>Foldes</surname><given-names>G.</given-names></name>,
<name name-style="western"><surname>Gatheral</surname><given-names>T.</given-names></name>,
<name name-style="western"><surname>Paschalaki</surname><given-names>K.
E.</given-names></name>, <name name-style="western"><surname>Lendvai</surname><given-names>Z.</given-names></name>,
<name name-style="western"><surname>Bagyura</surname><given-names>Z.</given-names></name>,
<name name-style="western"><surname>Nemeth</surname><given-names>T.</given-names></name>,
<name name-style="western"><surname>Skopal</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Merkely</surname><given-names>B.</given-names></name>,
<name name-style="western"><surname>Telcian</surname><given-names>A.
G.</given-names></name>, <name name-style="western"><surname>Gogsadze</surname><given-names>L.</given-names></name>,
<name name-style="western"><surname>Edwards</surname><given-names>M.
R.</given-names></name>, <name name-style="western"><surname>Gough</surname><given-names>P. J.</given-names></name>,
<name name-style="western"><surname>Bertin</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Johnston</surname><given-names>S.
L.</given-names></name>, <name name-style="western"><surname>Harding</surname><given-names>S. E.</given-names></name>,
<name name-style="western"><surname>Mitchell</surname><given-names>J.
A.</given-names></name></person-group> (<year>2014</year>)
<article-title>Pathogen sensing pathways in human embryonic stem cell
derived-endothelial cells: role of NOD1 receptors.</article-title>
<source>PLoS One</source>
<volume>9</volume>, <fpage>e91119</fpage>
<pub-id pub-id-type="pmid">24690886</pub-id></mixed-citation>
              </ref>
              <ref id="B26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starke</surname><given-names>R.
D.</given-names></name>, <name name-style="western"><surname>Ferraro</surname><given-names>F.</given-names></name>,
<name name-style="western"><surname>Paschalaki</surname><given-names>K.
E.</given-names></name>, <name name-style="western"><surname>Dryden</surname><given-names>N. H.</given-names></name>,
<name name-style="western"><surname>McKinnon</surname><given-names>T.
A.</given-names></name>, <name name-style="western"><surname>Sutton</surname><given-names>R. E.</given-names></name>,
<name name-style="western"><surname>Payne</surname><given-names>E.
M.</given-names></name>, <name name-style="western"><surname>Haskard</surname><given-names>D. O.</given-names></name>,
<name name-style="western"><surname>Hughes</surname><given-names>A.
D.</given-names></name>, <name name-style="western"><surname>Cutler</surname><given-names>D. F.</given-names></name>,
<name name-style="western"><surname>Laffan</surname><given-names>M.
A.</given-names></name>, <name name-style="western"><surname>Randi</surname><given-names>A. M.</given-names></name></person-group>
(<year>2011</year>) <article-title>Endothelial von Willebrand factor regulates
angiogenesis.</article-title>
<source>Blood</source>
<volume>117</volume>, <fpage>1071</fpage>–<lpage>1080</lpage>
<pub-id pub-id-type="pmid">21048155</pub-id></mixed-citation>
              </ref>
              <ref id="B27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starke</surname><given-names>R.
D.</given-names></name>, <name name-style="western"><surname>Paschalaki</surname><given-names>K. E.</given-names></name>,
<name name-style="western"><surname>Dyer</surname><given-names>C.
E.</given-names></name>,
<name name-style="western"><surname>Harrison-Lavoie</surname><given-names>K.
J.</given-names></name>, <name name-style="western"><surname>Cutler</surname><given-names>J. A.</given-names></name>,
<name name-style="western"><surname>McKinnon</surname><given-names>T.
A.</given-names></name>, <name name-style="western"><surname>Millar</surname><given-names>C. M.</given-names></name>,
<name name-style="western"><surname>Cutler</surname><given-names>D.
F.</given-names></name>, <name name-style="western"><surname>Laffan</surname><given-names>M. A.</given-names></name>,
<name name-style="western"><surname>Randi</surname><given-names>A.
M.</given-names></name></person-group> (<year>2013</year>)
<article-title>Cellular and molecular basis of von Willebrand disease: studies on
blood outgrowth endothelial cells.</article-title>
<source>Blood</source>
<volume>121</volume>, <fpage>2773</fpage>–<lpage>2784</lpage>
<pub-id pub-id-type="pmid">23355534</pub-id></mixed-citation>
              </ref>
              <ref id="B28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boutaud</surname><given-names>O.</given-names></name>,
<name name-style="western"><surname>Aronoff</surname><given-names>D.
M.</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>J. H.</given-names></name>,
<name name-style="western"><surname>Marnett</surname><given-names>L.
J.</given-names></name>, <name name-style="western"><surname>Oates</surname><given-names>J. A.</given-names></name></person-group>
(<year>2002</year>) <article-title>Determinants of the cellular specificity of
acetaminophen as an inhibitor of prostaglandin H(2) synthases.</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<volume>99</volume>, <fpage>7130</fpage>–<lpage>7135</lpage>
<pub-id pub-id-type="pmid">12011469</pub-id></mixed-citation>
              </ref>
              <ref id="B29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Potter</surname><given-names>C.
M.</given-names></name>, <name name-style="western"><surname>Lundberg</surname><given-names>M. H.</given-names></name>,
<name name-style="western"><surname>Harrington</surname><given-names>L.
S.</given-names></name>, <name name-style="western"><surname>Warboys</surname><given-names>C. M.</given-names></name>,
<name name-style="western"><surname>Warner</surname><given-names>T.
D.</given-names></name>, <name name-style="western"><surname>Berson</surname><given-names>R. E.</given-names></name>,
<name name-style="western"><surname>Moshkov</surname><given-names>A.
V.</given-names></name>, <name name-style="western"><surname>Gorelik</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Weinberg</surname><given-names>P.
D.</given-names></name>, <name name-style="western"><surname>Mitchell</surname><given-names>J. A.</given-names></name></person-group>
(<year>2011</year>) <article-title>Role of shear stress in endothelial cell
morphology and expression of cyclooxygenase isoforms.</article-title>
<source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>31</volume>, <fpage>384</fpage>–<lpage>391</lpage>
<pub-id pub-id-type="pmid">21127291</pub-id></mixed-citation>
              </ref>
              <ref id="B30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffey</surname><given-names>M.
J.</given-names></name>, <name name-style="western"><surname>Coles</surname><given-names>B.</given-names></name>,
<name name-style="western"><surname>Locke</surname><given-names>M.</given-names></name>,
<name name-style="western"><surname>Bermudez-Fajardo</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Williams</surname><given-names>P.
C.</given-names></name>, <name name-style="western"><surname>Jarvis</surname><given-names>G. E.</given-names></name>,
<name name-style="western"><surname>O’donnell</surname><given-names>V.
B.</given-names></name></person-group> (<year>2004</year>)
<article-title>Interactions of 12-lipoxygenase with phospholipase A2 isoforms
following platelet activation through the glycoprotein VI collagen
receptor.</article-title>
<source>FEBS Lett.</source>
<volume>576</volume>, <fpage>165</fpage>–<lpage>168</lpage>
<pub-id pub-id-type="pmid">15474031</pub-id></mixed-citation>
              </ref>
              <ref id="B31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iyú</surname><given-names>D.</given-names></name>,
<name name-style="western"><surname>Glenn</surname><given-names>J.
R.</given-names></name>, <name name-style="western"><surname>White</surname><given-names>A. E.</given-names></name>,
<name name-style="western"><surname>Johnson</surname><given-names>A.
J.</given-names></name>, <name name-style="western"><surname>Fox</surname><given-names>S. C.</given-names></name>,
<name name-style="western"><surname>Heptinstall</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>)
<article-title>The role of prostanoid receptors in mediating the effects of PGE(2)
on human platelet function.</article-title>
<source>Platelets</source>
<volume>21</volume>, <fpage>329</fpage>–<lpage>342</lpage>
<pub-id pub-id-type="pmid">20433310</pub-id></mixed-citation>
              </ref>
              <ref id="B32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katoh</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Ikeda</surname><given-names>H.</given-names></name>,
<name name-style="western"><surname>Murohara</surname><given-names>T.</given-names></name>,
<name name-style="western"><surname>Haramaki</surname><given-names>N.</given-names></name>,
<name name-style="western"><surname>Ito</surname><given-names>H.</given-names></name>,
<name name-style="western"><surname>Imaizumi</surname><given-names>T.</given-names></name></person-group> (<year>1998</year>)
<article-title>Platelet-derived 12-hydroxyeicosatetraenoic acid plays an important
role in mediating canine coronary thrombosis by regulating platelet glycoprotein
IIb/IIIa activation.</article-title>
<source>Circulation</source>
<volume>98</volume>, <fpage>2891</fpage>–<lpage>2898</lpage>
<pub-id pub-id-type="pmid">9860792</pub-id></mixed-citation>
              </ref>
              <ref id="B33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeung</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Apopa</surname><given-names>P.
L.</given-names></name>, <name name-style="western"><surname>Vesci</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Stolla</surname><given-names>M.</given-names></name>,
<name name-style="western"><surname>Rai</surname><given-names>G.</given-names></name>,
<name name-style="western"><surname>Simeonov</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Jadhav</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Fernandez-Perez</surname><given-names>P.</given-names></name>,
<name name-style="western"><surname>Maloney</surname><given-names>D.
J.</given-names></name>, <name name-style="western"><surname>Boutaud</surname><given-names>O.</given-names></name>,
<name name-style="western"><surname>Holman</surname><given-names>T.
R.</given-names></name>, <name name-style="western"><surname>Holinstat</surname><given-names>M.</given-names></name></person-group>
(<year>2013</year>) <article-title>12-lipoxygenase activity plays an important
role in PAR4 and GPVI-mediated platelet reactivity.</article-title>
<source>Thromb. Haemost.</source>
<volume>110</volume>, <fpage>569</fpage>–<lpage>581</lpage>
<pub-id pub-id-type="pmid">23784669</pub-id></mixed-citation>
              </ref>
              <ref id="B34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mais</surname><given-names>D.
E.</given-names></name>, <name name-style="western"><surname>Saussy</surname><given-names>D. L.</given-names><suffix>Jr</suffix></name>,
<name name-style="western"><surname>Magee</surname><given-names>D.
E.</given-names></name>, <name name-style="western"><surname>Bowling</surname><given-names>N. L.</given-names></name></person-group>
(<year>1990</year>) <article-title>Interaction of 5-HETE, 12-HETE, 15-HETE and
5,12-diHETE at the human platelet thromboxane A2/prostaglandin H2
receptor.</article-title>
<source>Eicosanoids</source>
<volume>3</volume>, <fpage>121</fpage>–<lpage>124</lpage><pub-id pub-id-type="pmid">2169775</pub-id></mixed-citation>
              </ref>
              <ref id="B35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vijil</surname><given-names>C.</given-names></name>,
<name name-style="western"><surname>Hermansson</surname><given-names>C.</given-names></name>,
<name name-style="western"><surname>Jeppsson</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Bergström</surname><given-names>G.</given-names></name>,
<name name-style="western"><surname>Hultén</surname><given-names>L.
M.</given-names></name></person-group> (<year>2014</year>)
<article-title>Arachidonate 15-lipoxygenase enzyme products increase platelet
aggregation and thrombin generation.</article-title>
<source>PLoS One</source>
<volume>9</volume>, <fpage>e88546</fpage>
<pub-id pub-id-type="pmid">24533104</pub-id></mixed-citation>
              </ref>
              <ref id="B36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Amor</surname><given-names>N.</given-names></name>,
<name name-style="western"><surname>Redondo</surname><given-names>P.
C.</given-names></name>, <name name-style="western"><surname>Bartegi</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Pariente</surname><given-names>J.
A.</given-names></name>, <name name-style="western"><surname>Salido</surname><given-names>G. M.</given-names></name>,
<name name-style="western"><surname>Rosado</surname><given-names>J.
A.</given-names></name></person-group> (<year>2006</year>)
<article-title>A role for 5,6-epoxyeicosatrienoic acid in calcium entry by de novo
conformational coupling in human platelets.</article-title>
<source>J. Physiol.</source>
<volume>570</volume>, <fpage>309</fpage>–<lpage>323</lpage><pub-id pub-id-type="pmid">16308346</pub-id></mixed-citation>
              </ref>
              <ref id="B37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>W.
L.</given-names></name>, <name name-style="western"><surname>Stubbe</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Ricciotti</surname><given-names>E.</given-names></name>,
<name name-style="western"><surname>Alamuddin</surname><given-names>N.</given-names></name>,
<name name-style="western"><surname>Ibrahim</surname><given-names>S.</given-names></name>,
<name name-style="western"><surname>Crichton</surname><given-names>I.</given-names></name>,
<name name-style="western"><surname>Prempeh</surname><given-names>M.</given-names></name>,
<name name-style="western"><surname>Lawson</surname><given-names>J.
A.</given-names></name>, <name name-style="western"><surname>Wilensky</surname><given-names>R. L.</given-names></name>,
<name name-style="western"><surname>Rasmussen</surname><given-names>L.
M.</given-names></name>, <name name-style="western"><surname>Puré</surname><given-names>E.</given-names></name>,
<name name-style="western"><surname>FitzGerald</surname><given-names>G.
A.</given-names></name></person-group> (<year>2012</year>)
<article-title>Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and
humans.</article-title>
<source>J. Clin. Invest.</source>
<volume>122</volume>, <fpage>1459</fpage>–<lpage>1468</lpage>
<pub-id pub-id-type="pmid">22406532</pub-id></mixed-citation>
              </ref>
              <ref id="B38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prévost</surname><given-names>N.</given-names></name>,
<name name-style="western"><surname>Mitsios</surname><given-names>J.
V.</given-names></name>, <name name-style="western"><surname>Kato</surname><given-names>H.</given-names></name>,
<name name-style="western"><surname>Burke</surname><given-names>J.
E.</given-names></name>, <name name-style="western"><surname>Dennis</surname><given-names>E. A.</given-names></name>,
<name name-style="western"><surname>Shimizu</surname><given-names>T.</given-names></name>,
<name name-style="western"><surname>Shattil</surname><given-names>S.
J.</given-names></name></person-group> (<year>2009</year>)
<article-title>Group IVA cytosolic phospholipase A2 (cPLA2alpha) and integrin
alphaIIbbeta3 reinforce each other’s functions during alphaIIbbeta3
signaling in platelets.</article-title>
<source>Blood</source>
<volume>113</volume>, <fpage>447</fpage>–<lpage>457</lpage>
<pub-id pub-id-type="pmid">18840708</pub-id></mixed-citation>
              </ref>
              <ref id="B39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patrignani</surname><given-names>P.</given-names></name>,
<name name-style="western"><surname>Panara</surname><given-names>M.
R.</given-names></name>, <name name-style="western"><surname>Greco</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Fusco</surname><given-names>O.</given-names></name>,
<name name-style="western"><surname>Natoli</surname><given-names>C.</given-names></name>,
<name name-style="western"><surname>Iacobelli</surname><given-names>S.</given-names></name>,
<name name-style="western"><surname>Cipollone</surname><given-names>F.</given-names></name>,
<name name-style="western"><surname>Ganci</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Créminon</surname><given-names>C.</given-names></name>,
<name name-style="western"><surname>Maclouf</surname><given-names>J.</given-names></name></person-group> (<year>1994</year>)
<article-title>Biochemical and pharmacological characterization of the
cyclooxygenase activity of human blood prostaglandin endoperoxide
synthases.</article-title>
<source>J. Pharmacol. Exp. Ther.</source>
<volume>271</volume>, <fpage>1705</fpage>–<lpage>1712</lpage><pub-id pub-id-type="pmid">7996488</pub-id></mixed-citation>
              </ref>
              <ref id="B40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rådmark</surname><given-names>O.</given-names></name>,
<name name-style="western"><surname>Werz</surname><given-names>O.</given-names></name>,
<name name-style="western"><surname>Steinhilber</surname><given-names>D.</given-names></name>,
<name name-style="western"><surname>Samuelsson</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>)
<article-title>5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health
and disease.</article-title>
<source>Biochim. Biophys. Acta</source>
<volume>1851</volume>, <fpage>331</fpage>–<lpage>339</lpage>
<pub-id pub-id-type="pmid">25152163</pub-id></mixed-citation>
              </ref>
              <ref id="B41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeForge</surname><given-names>L.
E.</given-names></name>, <name name-style="western"><surname>Kenney</surname><given-names>J. S.</given-names></name>,
<name name-style="western"><surname>Jones</surname><given-names>M.
L.</given-names></name>, <name name-style="western"><surname>Warren</surname><given-names>J. S.</given-names></name>,
<name name-style="western"><surname>Remick</surname><given-names>D.
G.</given-names></name></person-group> (<year>1992</year>)
<article-title>Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated
human whole blood. Separation of LPS- and cytokine-stimulated components using
anti-tumor necrosis factor and anti-IL-1 antibodies.</article-title>
<source>J. Immunol.</source>
<volume>148</volume>, <fpage>2133</fpage>–<lpage>2141</lpage><pub-id pub-id-type="pmid">1545121</pub-id></mixed-citation>
              </ref>
              <ref id="B42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ternowitz</surname><given-names>T.</given-names></name>,
<name name-style="western"><surname>Fogh</surname><given-names>K.</given-names></name>,
<name name-style="western"><surname>Kragballe</surname><given-names>K.</given-names></name></person-group> (<year>1988</year>)
<article-title>15-Hydroxyeicosatetraenoic acid (15-HETE) specifically inhibits
LTB4-induced chemotaxis of human neutrophils.</article-title>
<source>Skin Pharmacol.</source>
<volume>1</volume>, <fpage>93</fpage>–<lpage>99</lpage><pub-id pub-id-type="pmid">2856182</pub-id></mixed-citation>
              </ref>
              <ref id="B43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Z.
H.</given-names></name>, <name name-style="western"><surname>Bates</surname><given-names>E. J.</given-names></name>,
<name name-style="western"><surname>Ferrante</surname><given-names>J.
V.</given-names></name>, <name name-style="western"><surname>Hii</surname><given-names>C. S.</given-names></name>,
<name name-style="western"><surname>Poulos</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Robinson</surname><given-names>B.
S.</given-names></name>, <name name-style="western"><surname>Ferrante</surname><given-names>A.</given-names></name></person-group>
(<year>1997</year>) <article-title>Inhibition of stimulus-induced endothelial cell
intercellular adhesion molecule-1, E-selectin, and vascular cellular adhesion
molecule-1 expression by arachidonic acid and its hydroxy and hydroperoxy
derivatives.</article-title>
<source>Circ. Res.</source>
<volume>80</volume>, <fpage>149</fpage>–<lpage>158</lpage>
<pub-id pub-id-type="pmid">9012737</pub-id></mixed-citation>
              </ref>
              <ref id="B44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boisvert</surname><given-names>W.
A.</given-names></name>, <name name-style="western"><surname>Curtiss</surname><given-names>L. K.</given-names></name>,
<name name-style="western"><surname>Terkeltaub</surname><given-names>R.
A.</given-names></name></person-group> (<year>2000</year>)
<article-title>Interleukin-8 and its receptor CXCR2 in
atherosclerosis.</article-title>
<source>Immunol. Res.</source>
<volume>21</volume>, <fpage>129</fpage>–<lpage>137</lpage>
<pub-id pub-id-type="pmid">10852110</pub-id></mixed-citation>
              </ref>
              <ref id="B45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>FitzGerald</surname><given-names>G.
A.</given-names></name>, <name name-style="western"><surname>Oates</surname><given-names>J. A.</given-names></name>,
<name name-style="western"><surname>Hawiger</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Maas</surname><given-names>R.
L.</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>L. J.</given-names><suffix>II</suffix></name>,
<name name-style="western"><surname>Lawson</surname><given-names>J.
A.</given-names></name>, <name name-style="western"><surname>Brash</surname><given-names>A. R.</given-names></name></person-group>
(<year>1983</year>) <article-title>Endogenous biosynthesis of prostacyclin and
thromboxane and platelet function during chronic administration of aspirin in
man.</article-title>
<source>J. Clin. Invest.</source>
<volume>71</volume>, <fpage>676</fpage>–<lpage>688</lpage>
<pub-id pub-id-type="pmid">6338043</pub-id></mixed-citation>
              </ref>
              <ref id="B46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>J.
P.</given-names></name>, <name name-style="western"><surname>Haddad</surname><given-names>E. V.</given-names></name>,
<name name-style="western"><surname>Taylor</surname><given-names>M.
B.</given-names></name>, <name name-style="western"><surname>Oram</surname><given-names>D.</given-names></name>,
<name name-style="western"><surname>Blakemore</surname><given-names>D.</given-names></name>,
<name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name>,
<name name-style="western"><surname>Boutaud</surname><given-names>O.</given-names></name>,
<name name-style="western"><surname>Oates</surname><given-names>J.
A.</given-names></name></person-group> (<year>2012</year>)
<article-title>Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in
metabolic syndrome.</article-title>
<source>Hypertension</source>
<volume>59</volume>, <fpage>719</fpage>–<lpage>725</lpage>
<pub-id pub-id-type="pmid">22311905</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
